Medacta Group Dirección

Dirección controles de criterios 4/4

El CEO de Medacta Group's es Francesco Siccardi , nombrado en Nov 2018, tiene una permanencia de 5.42 años. compensación anual total es €1.86M, compuesta por 21.3% salario y 78.7% primas, incluidas acciones y opciones de la empresa. posee directamente un 19.9% de las acciones de la empresa, por valor de CHF441.78M. La antigüedad media del equipo directivo y de la junta directiva es de 10.8 años y 5.3 años, respectivamente.

Información clave

Francesco Siccardi

Chief Executive Officer (CEO)

€1.9m

Compensación total

Porcentaje del salario del CEO	21.3%
Permanencia del CEO	5.5yrs
Participación del CEO	19.9%
Permanencia media de la dirección	10.8yrs
Promedio de permanencia en la Junta Directiva	5.3yrs

Actualizaciones recientes de la dirección

We Discuss Why Medacta Group SA's (VTX:MOVE) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year

May 01

Recent updates

We Discuss Why Medacta Group SA's (VTX:MOVE) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year

May 01

If EPS Growth Is Important To You, Medacta Group (VTX:MOVE) Presents An Opportunity

Oct 17

Is Medacta Group (VTX:MOVE) Using Too Much Debt?

Sep 29

Calculating The Intrinsic Value Of Medacta Group SA (VTX:MOVE)

Aug 11

Is Now The Time To Look At Buying Medacta Group SA (VTX:MOVE)?

Jul 27

Be Wary Of Medacta Group (VTX:MOVE) And Its Returns On Capital

Jul 03

At CHF117, Is It Time To Put Medacta Group SA (VTX:MOVE) On Your Watch List?

Apr 28

Is Medacta Group (VTX:MOVE) A Risky Investment?

Apr 08

Is Now An Opportune Moment To Examine Medacta Group SA (VTX:MOVE)?

Dec 25

Capital Allocation Trends At Medacta Group (VTX:MOVE) Aren't Ideal

Dec 09

Does Medacta Group (VTX:MOVE) Have A Healthy Balance Sheet?

Nov 09

Why Medacta Group SA (VTX:MOVE) Could Be Worth Watching

Sep 16

The Returns On Capital At Medacta Group (VTX:MOVE) Don't Inspire Confidence

Aug 20

Here's Why Medacta Group (VTX:MOVE) Has Caught The Eye Of Investors

Jul 02

Should You Think About Buying Medacta Group SA (VTX:MOVE) Now?

May 28

Medacta Group (VTX:MOVE) Is Reinvesting At Lower Rates Of Return

May 12

These 4 Measures Indicate That Medacta Group (VTX:MOVE) Is Using Debt Reasonably Well

Mar 31

Does Medacta Group (VTX:MOVE) Deserve A Spot On Your Watchlist?

Mar 17

Capital Investments At Medacta Group (VTX:MOVE) Point To A Promising Future

Feb 07

Should You Investigate Medacta Group SA (VTX:MOVE) At CHF133?

Dec 10

Medacta Group (VTX:MOVE) Knows How To Allocate Capital

Nov 05

Here's Why Medacta Group (VTX:MOVE) Can Manage Its Debt Responsibly

Sep 30

Is It Too Late To Consider Buying Medacta Group SA (VTX:MOVE)?

Aug 26

Medacta Group (VTX:MOVE) May Have Issues Allocating Its Capital

Jul 20

Should You Investigate Medacta Group SA (VTX:MOVE) At CHF119?

May 19

We Think Medacta Group (VTX:MOVE) Can Stay On Top Of Its Debt

Apr 05

What You Need To Know About Medacta Group SA's (VTX:MOVE) Investor Composition

Mar 02

Is Medacta Group SA's (VTX:MOVE) 7.6% ROE Better Than Average?

Feb 02

The Medacta Group (VTX:MOVE) Share Price Has Gained 24% And Shareholders Are Hoping For More

Jan 12

Returns On Capital At Medacta Group (VTX:MOVE) Paint An Interesting Picture

Dec 21

Should You Use Medacta Group's (VTX:MOVE) Statutory Earnings To Analyse It?

Dec 03

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Francesco Siccardi en comparación con los beneficios de Medacta Group?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	€2m	€396k	€47m
Sep 30 2023	n/a	n/a	€49m
Jun 30 2023	n/a	n/a	€50m
Mar 31 2023	n/a	n/a	€48m
Dec 31 2022	€2m	€372k	€46m
Sep 30 2022	n/a	n/a	€47m
Jun 30 2022	n/a	n/a	€47m
Mar 31 2022	n/a	n/a	€49m
Dec 31 2021	€2m	€354k	€52m
Sep 30 2021	n/a	n/a	€54m
Jun 30 2021	n/a	n/a	€57m
Mar 31 2021	n/a	n/a	€47m
Dec 31 2020	€1m	€339k	€37m
Sep 30 2020	n/a	n/a	€24m
Jun 30 2020	n/a	n/a	€10m
Mar 31 2020	n/a	n/a	€11m
Dec 31 2019	€843k	€247k	€12m

Compensación vs. Mercado: La compensación total ($USD1.99M) de Francesco está en línea con el promedio de empresas de tamaño similar en el mercado Swiss ($USD1.71M).

Compensación vs. Ingresos: La compensación de Francesco ha sido consistente con los resultados de la empresa en el último año.

CEO

Francesco Siccardi (46 yo)

5.5yrs

Permanencia

€1,861,824

Compensación

Dr. Francesco Siccardi has been Chief Executive Officer of Medacta Group SA since November 1, 2018. He is a Member of the Board of Directors of Surgical Practice Resource Group SA, Lugano since 2015 and of...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Alberto Siccardi	Founder & Non Executive Chairman	6.3yrs	€352.21k	10.2% € 235.7m
Francesco Siccardi	Chief Executive Officer	5.5yrs	€1.86m	19.9% € 460.0m
Corrado Farsetta	Chief Financial Officer	13.3yrs	sin datos	sin datos
Gianluca Olgiati	Senior Director of Global Marketing	no data	sin datos	sin datos
Asif Hussain	Chief People Officer	no data	sin datos	sin datos
Alessandro Siccardi	Chief Supply Chain Officer	8.3yrs	sin datos	19.8% € 457.8m
Filippo Cappelli	Head of IT	no data	sin datos	sin datos
Giovanni Galli	Chief Commercial Officer	no data	sin datos	sin datos
Massimiliano Bernardoni	Chief Innovation Officer	no data	sin datos	sin datos
Donato Cortesi	Secretary of the Board	no data	sin datos	sin datos

10.8yrs

Permanencia media

50.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de MOVE es experimentado (10.8 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Alberto Siccardi	Founder & Non Executive Chairman	6.3yrs	€352.21k	10.2% € 235.7m
Victor Balli	Lead Independent Director	5.3yrs	€231.19k	0.013% € 290.1k
Riccardo Braglia	Independent Director	3.4yrs	€128.89k	0.16% € 3.8m
Philippe Weber	Independent Director	5.2yrs	€152.33k	sin datos
Maria Siccardi Tonolli	Non-executive Director	6.3yrs	€137.62k	19.8% € 457.8m

5.3yrs

Permanencia media

63yo

Promedio de edad

Junta con experiencia: La junta directiva de MOVE se considera experimentada (5.3 años de antigüedad promedio).

Medacta Group Dirección

Dirección controles de criterios 4/4

Información clave

Actualizaciones recientes de la dirección

We Discuss Why Medacta Group SA's (VTX:MOVE) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year

Insufficient new directors

Medacta Group SA, Annual General Meeting, May 25, 2021

Recent updates

We Discuss Why Medacta Group SA's (VTX:MOVE) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year

Medacta Group (VTX:MOVE) Has A Pretty Healthy Balance Sheet

Is Now An Opportune Moment To Examine Medacta Group SA (VTX:MOVE)?

Dividend of CHF0.55 announced

Full year 2023 earnings: EPS and revenues miss analyst expectations

Does Medacta Group (VTX:MOVE) Deserve A Spot On Your Watchlist?

Medacta Group (VTX:MOVE) Will Be Hoping To Turn Its Returns On Capital Around

Insufficient new directors

Getting In Cheap On Medacta Group SA (VTX:MOVE) Might Be Difficult

Calculating The Intrinsic Value Of Medacta Group SA (VTX:MOVE)

Is Now The Time To Look At Buying Medacta Group SA (VTX:MOVE)?

Returns On Capital Signal Tricky Times Ahead For Medacta Group (VTX:MOVE)

Medacta Group SA to Report Q4, 2023 Results on Feb 02, 2024

If EPS Growth Is Important To You, Medacta Group (VTX:MOVE) Presents An Opportunity

Is Medacta Group (VTX:MOVE) Using Too Much Debt?

First half 2023 earnings released: EPS: €1.46 (vs €1.28 in 1H 2022)

Calculating The Intrinsic Value Of Medacta Group SA (VTX:MOVE)

Is Now The Time To Look At Buying Medacta Group SA (VTX:MOVE)?

Be Wary Of Medacta Group (VTX:MOVE) And Its Returns On Capital

At CHF117, Is It Time To Put Medacta Group SA (VTX:MOVE) On Your Watch List?

Upcoming dividend of CHF0.54 per share at 0.5% yield

Is Medacta Group (VTX:MOVE) A Risky Investment?

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Medacta Group SA to Report Fiscal Year 2022 Results on Feb 03, 2023

Is Now An Opportune Moment To Examine Medacta Group SA (VTX:MOVE)?

Capital Allocation Trends At Medacta Group (VTX:MOVE) Aren't Ideal

Does Medacta Group (VTX:MOVE) Have A Healthy Balance Sheet?

Medacta Group SA to Report Q2, 2023 Results on Sep 22, 2023

Why Medacta Group SA (VTX:MOVE) Could Be Worth Watching

First half 2022 earnings released: EPS: €1.28 (vs €1.49 in 1H 2021)

Medacta Group SA Revises Revenue Growth Guidance for the Full Year 2022

The Returns On Capital At Medacta Group (VTX:MOVE) Don't Inspire Confidence

Medacta Group SA Provides Revenue Guidance for the Year 2022

Here's Why Medacta Group (VTX:MOVE) Has Caught The Eye Of Investors

Should You Think About Buying Medacta Group SA (VTX:MOVE) Now?

Medacta Group SA Approves Distribution

Medacta Group (VTX:MOVE) Is Reinvesting At Lower Rates Of Return

These 4 Measures Indicate That Medacta Group (VTX:MOVE) Is Using Debt Reasonably Well

Consensus forecasts updated

Does Medacta Group (VTX:MOVE) Deserve A Spot On Your Watchlist?

Full year 2021 earnings: EPS misses analyst expectations

Capital Investments At Medacta Group (VTX:MOVE) Point To A Promising Future

Medacta Launches 360° (Anterior and Posterior) Cervical Platform, Highlighting MySpine Cervical, a Further Enhancement to the MySolutions Personalized Ecosystem

Should You Investigate Medacta Group SA (VTX:MOVE) At CHF133?

Medacta Group (VTX:MOVE) Knows How To Allocate Capital

Here's Why Medacta Group (VTX:MOVE) Can Manage Its Debt Responsibly

First half 2021 earnings released: EPS €1.49 (vs €0.48 in 1H 2020)

Medacta Group SA Confirms Revenue Guidance for the Year 2021

Is It Too Late To Consider Buying Medacta Group SA (VTX:MOVE)?

Medacta Group (VTX:MOVE) May Have Issues Allocating Its Capital

Medacta Announces Successful Completion of First Reverse Shoulder Arthroplasties Using NextAR Augmented Reality Surgical Platform

Should You Investigate Medacta Group SA (VTX:MOVE) At CHF119?

Medacta Announces First U.S. Surgery with the New M.U.S.T. Lt System in Minimally Invasive Spine Surgery

We Think Medacta Group (VTX:MOVE) Can Stay On Top Of Its Debt

Full year 2020 earnings released: EPS €1.86 (vs €0.59 in FY 2019)

Medacta Announces the Launch of MySpine for S2-Alar-Iliac Fixation and Further Enhances its MySolutions Personalized Ecosystem

What You Need To Know About Medacta Group SA's (VTX:MOVE) Investor Composition

Medacta Adds the MyHip Planner and the MyHip Verifier Tools to Its Medicine Solutions for Hip Replacement

Is Medacta Group SA's (VTX:MOVE) 7.6% ROE Better Than Average?

New 90-day high: CHF103

Medacta Group SA to Report Q2, 2021 Final Results on Sep 10, 2021

New 90-day high: CHF91.60

The Medacta Group (VTX:MOVE) Share Price Has Gained 24% And Shareholders Are Hoping For More

Medacta Group SA, Annual General Meeting, May 25, 2021

Medacta Announces Successful Completion of the First TKA Surgery in the U.S. with NextAR Augmented Reality-Based Surgical Platform

Returns On Capital At Medacta Group (VTX:MOVE) Paint An Interesting Picture

Should You Use Medacta Group's (VTX:MOVE) Statutory Earnings To Analyse It?

New 90-day low: CHF82.40

Medacta Expands Its Knee Offerings with New SensiTiN System with Low Metal Ion Release

New 90-day high: CHF90.00

First half earnings released

Medacta Group SA to Report Fiscal Year 2020 Results on Jan 21, 2021